NICE rejects Vitrakvi to treat neurotrophic tyrosine receptor kinase fusion-positive solid tumours.- Bayer HealthCare

The National Institute for Health and Care Excellence (NICE) has rejected Vitrakvi (larotrectinib) from Bayer as its current price, it does not have the “potential to be cost-effective.” The guidance related to Vitrakvi being used in advanced neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children who have no satisfactory treatment options. NICE considered that cost-effectiveness calculations for the drug are “very uncertain," adding that the drug’s benefit over existing treatment options is unknown. NICE said it is difficult to know how well [Vitrakvi] works because it has not been compared in the trials with other treatments. Germany’s cost-effectiveness agency, IQWiG, also rejected Vitrakvi on insufficient data. There are around 600–700 people have solid tumours with NTRK gene fusions .